O

Orca Bio

Develops and commercializes safer cell therapies

Technician - Quality Control, Night Shift

Full-TimePosted on 10/19/2026
$65.5k - $70.9k/yr+ Pre-IPO equity + Annual bonus
Mid
Bachelor's, Associate's
Sacramento, CA, USA
In PersonMust be able to work at either of the two Sacramento locations based on operational needs.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • An Associate of Science or Bachelor of Science degree in a relevant scientific discipline, such as biology or microbiology, is required.
  • High attention to detail and a commitment to data integrity are required.
  • Strong organizational, communication, and problem-solving skills are required.
  • Ability to work both independently and collaboratively in a fast-paced, regulated setting is required.
  • Flexibility and responsiveness to changing priorities and team needs are required.
  • Must have visual acuity of 20/20, corrected or uncorrected, and normal color vision to safely perform visual inspection of materials, equipment, and labeling, including distinguishing color-coded components in a GMP environment.
  • Must meet cleanroom gowning requirements, including wearing full gowning (face coverings, gloves, hoods, and goggles) for up to three consecutive hours, minimal movement in the cleanroom, and working with or around human blood, blood-derived materials, cells, other biological materials, and alcohol-based sprays. Cosmetics, jewelry, and facial piercings are not permitted in the cleanroom, and skin conditions that cause shedding must be disclosed.
  • Must be comfortable regularly participating in video-based meetings.
  • Must be able to work at either Sacramento location based on operational needs.
  • May be required to work scheduled overtime, weekends, or holidays based on business needs.
Responsibilities
  • Perform basic to moderately complex analytical tests following current Good Manufacturing Practice (cGMP) guidelines.
  • Test routine and non-routine samples and document results accurately and compliantly.
  • Maintain, calibrate, and troubleshoot laboratory equipment to ensure functionality.
  • Prepare reagents and aliquot samples, using aseptic techniques when needed.
  • Monitor and maintain inventory of laboratory supplies.
  • Support assay transfers, validations, and equipment qualifications.
  • Aliquot samples as required, including aseptic aliquoting.
  • Participate in group and project teamwork, project improvements, and process improvements.
  • Work cross-functionally with Manufacturing, Quality Control, and Quality Assurance to resolve issues and implement corrective actions.
  • Follow all cGMP documentation and procedural standards.
  • Perform additional duties as assigned to support the Quality team.
Desired Qualifications
  • Experience with analytical assays such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), or polymerase chain reaction (PCR) is preferred.
  • Familiarity with aseptic technique in a GMP or biotechnology setting is preferred.

About the company

Orca Bio develops and commercializes cell therapies to improve outcomes for patients. It works by researching, developing, and producing therapies that use the body’s own cells to treat diseases, with products sold to healthcare providers who administer them to patients. The company aims to enhance the safety and effectiveness of cell therapies, making treatments more reliable for conditions that lack good options. Orca Bio differentiates itself through its focus on delivering safer, more effective therapies and by fostering a strong team culture with active stakeholder communication, including a regularly updated newsroom. Overall, its goal is to expand access to improved cell therapies and become a leading player in the cell therapy market.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$542M

Headquarters

North Fair Oaks, California

Founded

2016

Get referred to Orca Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on June 30, 2026 validates Orca Bio's platform and pipeline.
  • The company raised $250 million in December 2025, funding launch and expansion.
  • Princeton capacity and Sacramento hiring support commercialization and faster nationwide patient delivery.

What critics are saying

  • TREGZI costs $428,000, forcing transplant centers and payers into tough coverage fights.
  • Complex donor-specific manufacturing can bottleneck supply, delaying launches beyond the planned 25 centers.
  • Any post-marketing safety signal or FDA CMC issue would cripple Orca Bio's only commercial product.

What makes Orca Bio unique

  • Orca Bio's TREGZI won FDA approval on June 30, 2026, first precision cell therapy.
  • Its donor-derived regulatory T-cell design directly reduces chronic GVHD after transplant.
  • Princeton and Sacramento manufacturing create a bicoastal vein-to-vein network for personalized production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Unlimited Paid Time Off
  • 401(k) Retirement Plan
  • Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

3%

2 year growth

0%
Associated Press
Jul 1st, 2026
FDA approves Tregzi, first donor immune cell therapy cutting serious transplant complications in blood cancer patients by 70%

The US Food and Drug Administration has approved Tregzi, the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult blood cancer patients undergoing stem cell transplantation. The treatment uses donor-derived immune cells to help fight cancer whilst reducing the risk of chronic GVHD, a serious complication where transplanted donor cells attack the patient's body. In the PRECISION-T trial involving 187 patients, 78% of those receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% receiving standard transplants. Only 12.6% of Tregzi patients developed serious chronic GVHD within one year versus 44% in the control group. The treatment, developed by Orca Biosystems, received Orphan Drug and Regenerative Medicine Advanced Therapy designations.

Fierce Pharma
Jul 1st, 2026
Orca Bio secures FDA approval for $428K cell therapy Tregzi, eyes potential IPO

Orca Bio has secured FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. The allogeneic regulatory T cell-based immunotherapy is approved as an alternative stem cell transplant to improve survival free of chronic graft-versus-host disease in adults with hematological malignancies. In the phase 3 Precision-T trial involving 187 patients, 78% who received Tregzi were alive and free from chronic GVHD at one year, compared to 38% with standard transplants—a 74% improvement. Overall survival was 94% versus 83%. Orca is pricing Tregzi at $428,000 wholesale acquisition cost. The company recently raised $250 million and is launching at select centres, aiming for 25 by year-end. CEO Nate Fernhoff said the company is "well capitalised" for launch but didn't rule out a future IPO.

Associated Press
Jun 30th, 2026
Orca Bio's TREGZI becomes first FDA-approved precision cell therapy for blood cancer transplants

Orca Bio has received US FDA approval for TREGZI, the first precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematological malignancies. The therapy uses donor cells to reconstitute the immune system whilst suppressing graft-versus-host disease (GVHD). The approval is based on the Phase 3 Precision-T study of 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome and mixed-phenotype acute leukaemia. Results showed 78% chronic GVHD-free survival at 12 months with TREGZI compared to 38% with conventional transplant. Overall survival was 94% versus 83%, whilst non-relapse mortality was 3% compared to 13%. TREGZI is a personalised treatment manufactured for each patient using living cells from a matched donor.

San Francisco Biotechnology Network
Jun 15th, 2026
Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval.

Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. June 15, 2026 san francisco biotechnology network news news, syndication comments off on orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. Orca Bio, a biotechnology company that works in precision cell therapy, has expanded its Sacramento workforce and added an East Coast manufacturing center in Princeton, New Jersey, as it prepares for commercialization. Click here to view original post

Business Wire
Jun 15th, 2026
Orca Bio expands manufacturing for Orca-T launch with East Coast facility and tripled workforce

Orca Bio has expanded its manufacturing capabilities ahead of the potential launch of its lead cell therapy, Orca-T, adding East Coast manufacturing capacity in Princeton, New Jersey, and tripling its West Coast manufacturing workforce in Sacramento, California. The Princeton facility will serve as a strategic East Coast manufacturing bridge, initially producing therapies for ongoing clinical programmes and supporting commercial production following potential FDA approval. The bicoastal network aims to reduce "vein-to-vein" time for patients nationwide. Orca Bio has more than tripled its Sacramento operations team over the past year, enhancing expertise in manufacturing, supply chain logistics and quality assurance. Orca-T's Biologics License Application is under FDA review, with a target action date of 6 July 2026.